Kornimate/medical-research-clean huggingface dataset:
transcriptomic analysis and optical coherence tomography combined for patients with basal cell carcinoma

Conditions: Basal Cell Carcinomas

Summary: the goal of this observational study is to learn if tape strip for transcriptomic (rna) analysis and optical coherence tomography (oct) combined can optimize noninvasive management of basal cell carcinoma (bcc) patients. the main question of the study is to examine if the combination of these two techniques, transcriptomic and oct, can improve noninvasive detection of human bccs. all included patients will undergo 1) an oct scan and 2) a tape strip collection for transcriptomic analysis from the same bcc.


Eligibility criteria:
inclusion criteria: * patients \> 18 years with clinical suspicious bcc for inclusion in the study and bcc histopathology diagnosis for inclusion in our analysis. exclusion criteria: * patients with a bcc in areas not amenable to oct (e.g., around the eye).

Keywords: basal cell carcinoma optical coherence tomography transcriptomics tape strip skin cancer keratinocyte carcinoma
development of knee osteoarthritis after arthroscopic partial resection of degenerative meniscus tear

Conditions: Osteoarthritis of the Knee; Arthroscopy; Meniscal Tear

Summary: it has been previously demonstrated that the risk for the development of knee osteoarthritis is increased after both meniscus tear and meniscectomy. however, it is still unclear whether this is due to the meniscus tear per se, the surgery, or whether the development of knee osteoarthritis is completely independent of the two. accordingly, the aim of the study is to investigate the effect of arthroscopic partial meniscectomy on the development of knee osteoarthritis 2 to 10 years after the procedure.

it has been previously demonstrated that the risk for the development/progression of knee osteoarthritis is increased after both meniscus tear and meniscectomy. however, it is still unclear whether this is due to the meniscus tear per se (i.e., adverse mechanical effect on knee cartilage), the surgery (resection of the meniscus, and subsequent loss of cushion within the knee), or whether the development of knee osteoarthritis is completely independent of the two. accordingly, the aim of the study is to investigate the effect of arthroscopic partial meniscectomy on the development of knee osteoarthritis 2 to 10 years after the procedure. patients included in the study will be randomized into one of two groups: arthroscopic partial meniscectomy and diagnostic arthroscopy (sham-surgery). the presence of knee osteoarthritis will be assessed preoperatively and 2, 5, and 10 years after the operation.

Eligibility criteria:
inclusion criteria: 1. age: 35 to 65 years of age. 2. a pain located on the medial joint line of the knee that has persistent at least for 3 months. 3. pain that can be provoked by palpation or compression of the joint line or a positive mcmurray sign. 4. tear of the medial meniscus on mri. 5. degenerative rupture of the medial meniscus confirmed at arthroscopy. exclusion criteria: 1. acute, trauma-induced onset of symptoms. 2. locking or painful snapping of the knee joint. 3. a surgical operation performed on the affected knee. 4. osteoarthritis of the medial compartment of the knee (determined by clinical criteria of the acr). 5. osteoarthritis on knee radiographs (kellgren-lawrence \> 1). 6. acute (within the previous year) fractures of the knee. 7. decreased range of motion of the knee. 8. instability of the knee. 9. mri assessment showing a tumor or any other complaint requiring surgical or other means of treatment. 10. arthroscopic assessment showing anything other than a degenerative tear of the medial meniscus requiring surgical intervention.

Keywords: sham-surgery development of osteoarthritis randomized, double-blinded, placebo-controlled
a project ensuring quality and cooperation in the chronic obstructive pulmonary disease (copd) treatment

Conditions: COPD; Chronic Diseases

Summary: the purpose of this study is to ensure the quality of the copd treatment in primary care by implementing planned follow-up visits, where the disease condition is evaluated and optimised in accordance with the national copd recommendations. if relevant the general practitioner (gp) will refer patients to copd rehabilitation conducted by relevant municipality rehabilitation teams. secondarily the purpose is to improve collaboration and communication between the local hospital pulmonologist, gps and the municipality rehabilitation team


Eligibility criteria:
inclusion criteria: * copd diagnose, verified by spirometry * having given informed consent exclusion criteria: -

Keywords: quality assurance rehabilitation chronic care model copd
pharmacokinetics in end stage renal disease patients

Conditions: Healthy Volunteers; Renal Failure

Summary: the study is a multicentre, open label, phase i, two arms study to compare pharmacokinetic of firibastat after a single oral dose of firibastat 500 mg in fourteen healthy male volunteers and in fourteen end stage renal disease (esrd) patients not yet in dialysis.

it is planned to enroll a total of 28 subjects to receive a single oral dose of investigational medicinal product (imp): 14 esrd patients will be enrolled in three hungarian centres (1st arm) and 14 healthy volunteers will be enrolled by eurofins optimed in gières, france (2nd arm). subjects will be screened for eligibility to participate in the study up to 21 days prior to the first administration. for both arm, subjects will be admitted into the clinical research unit (cru) on day -3. on the morning of day 1, subjects will receive a single 500 mg oral dose of firibastat following an overnight fast (i.e., at least 10 hours). subjects will be confined to the cru until discharge on day 3 with pk blood sample draws for measurement of firibastat and its main metabolites being taken throughout the confinement. a follow-up post study visit will occur on day 10 post-dose to ensure the ongoing wellbeing of the subjects.

Eligibility criteria:
inclusion criteria: * male subjects, aged 18 to 55 years inclusive; * non-smoker subject or smoker of not more than 5 cigarettes a day; exclusion criteria: * positive hepatitis b surface (hbs) antigen or anti hepatitis c virus (hcv) antibody, or positive results for human immunodeficiency virus (hiv) 1 or 2 tests); * history or presence of drug or alcohol abuse (alcohol consumption \> 40 grams/day);
effects of postoperative kinesio taping in weber type b lateral malleolar fractures

Conditions: Ankle Fractures; Syndesmotic Injuries; Postoperative Rehabilitation

Summary: this randomized controlled trial aimed to evaluate the effects of postoperative kinesio taping on pain, range of motion, and edema in patients undergoing surgical fixation for weber type b lateral malleolar fractures.

patients with weber type b lateral malleolar fractures treated surgically were randomized into two groups: a control group receiving standard rehabilitation and an intervention group receiving additional kinesio taping. outcomes assessed included visual analog scale (vas) pain scores, dorsiflexion range of motion, and circumferential edema measurements at 1, 7, and 28 days postoperatively.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years * patients diagnosed with isolated weber type b lateral malleolar fractures requiring surgical fixation * surgery performed within 7 days of injury * written informed consent provided exclusion criteria: * open fractures * associated fractures of the medial or posterior malleolus requiring fixation * polytrauma patients * history of previous ankle fractures or surgeries on the affected side * neurological or vascular compromise of the affected limb * known allergy to adhesive materials

Keywords: ankle fractures, kinesiology
characterization of post-operative pain trajectories over seven days and links with chronicity

Conditions: Surgical Procedures, Operative; Pain; Chronic Pain

Summary: the main objective of this study is to establish the postoperative "pain pathways" observed from d1 to d7 in the context of the current management after orthopedic, digestive, obstetrics and gynecology, urology, neurosurgery, vascular and thoracicn surgeries.

the secondary objectives of this study are: a. to assess the incidence of post-surgical chronic pain (pscp) chronic 3 months post intervention. b. to asses the incidence of neuropathic type pain (dn4 questionnaire) at 3 months post intervention. c. to study the potential links between pain trajectories and the presence or absence of pscp. d. to study the potential links between the presence or absence of pscp and known risk factors for pscp (patient-related data, data on the surgery, anesthesia data).

Eligibility criteria:
inclusion criteria: * the patient must be insured or beneficiary of a health insurance plan * the patient is available for 3 months of follow-up * the patient has undergone a planned surgical procedure in one of the participating departments * the patient is willing and able to respond to the study questionnaires (hads, pcs, en, dn4) exclusion criteria: * the patient is participating in another study * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, under tutorship or curatorship * it is impossible to correctly inform the patient * patient admitted to the icu and still intubated at day 1

Keywords: pain trajectory
precoce medical care by the mobil support for patients with glioblastoma

Conditions: Glioblastoma

Summary: most patients with glioblastoma have impaired cognitive function, autonomy, and quality of life. this clinical situation, combined with a limited life expectancy, makes the preservation of quality of life a major objective, in a supportive environment that respects family integration. this is especially true since there is an established relationship between health-related quality of life, as measured by questionnaires. in this context, and despite the lack of impact on overall survival, improving quality of life becomes a priority objective in recent phase iii trials. the feasibility of introducing early accompaniment in gbm should be assessed in the diagnostic and therapeutic announcement environment. in order to measure the expected impact as favorable in the patient and his family, a broad survey of the classic domains of quality of life and more specifically dedicated to neurological symptomatology.

glioblastomas are the most common primary malignant tumours of the central nervous system.they represent about 2000 new cases per year in france. despite active treatments including surgery, radiotherapy and chemotherapy, patient survival is limited without possible cure. most patients with glioblastoma have impaired cognitive function, autonomy, and quality of life. exploration of verbal memory in these patients shows that its deterioration is correlated with a more unfavourable prognosis, after adjustment with other usual prognostic factors. this clinical situation, combined with a limited life expectancy, makes the preservation of quality of life a major objective, in a supportive environment that respects family integration. this is especially true since there is an established relationship between health-related quality of life, as measured by questionnaires. the feasibility of introducing early accompaniment in gbm should be assessed in the diagnostic and therapeutic announcement environment. in order to measure the expected impact as favorable in the patient and his family, a broad survey of the classic domains of quality of life and more specifically dedicated to neurological symptomatology.

Eligibility criteria:
inclusion criteria: * adult patient ( ≥ 18 years), * histological diagnosis of glioblastoma * oncology caret at icm (regardless of treatment: stupp protocol, chemotherapy alone, targeted therapy, etc.); * patient consent signed after informed information. exclusion criteria: * patient unable to consent to the study * major impairment of the general health : performance status oms =4; * patient not affiliated with a french social security

Keywords: supportive care mobil unit
preventing recurrences of chronic subdural hematoma in adult patients by middle meningeal artery embolization

Conditions: Hematoma, Subdural, Chronic

Summary: patients with a chronic subdural hematoma (csdh), that is, a blood accumulation between two meninges developing over a long period of time, often have recurrent bleedings after an initial operation. the study aims to show that additional surgery reduces the risk of recurrent bleeding. the additional procedure aims to block small blood vessels in the skull with tiny plastic particles. the small blood vessels are embolized using x-rays and a contrast medium and a fine tube that is inserted into the diseased vessels of the head via the groin. patients of full age who have undergone burr hole trepanation as a first operation, i.e. a blood drain through a hole in the cranial cavity, can participate in the study. participating patients are randomly assigned to a control group with treatment according to clinical routine or a treatment group with an additional occlusion of the blood vessels in the skull. in addition, patients can consent to a genetic test to determine the relationship between a coagulation factor and the risk of recurrence of the hematoma. in order to record the test results, check-up examinations are carried out after one and three months.


Eligibility criteria:
inclusion criteria: 1. patients who have undergone surgery by means of one or more burr hole trepanations during the first manifestation of a csdh (unihemispherical or bihemispherical) detected by computed tomography or magnetic resonance tomography 2. age ≥18 years 3. sufficient compliance and ability to consent 4. patient's informed consent for surgical as well as endovascular interventional procedure and participation in the study exclusion criteria: 1. conservatively treated csdh 2. radiological evidence of an acute or subacute subdural hematoma, subarachnoid hemorrhage, intracerebral hematoma or epidural hematoma 3. surgical technique: craniotomy, craniectomy, bilateral burr hole trepanation 4. angiography cannot be performed within 72 hours after surgery 5. age \<18 years 6. supervisory relationship 7. pregnancy 8. lack of informed consent 9. lack of compliance 10. homozygous factor xiii deficiency with residual activity \<10%
ambulatory surgical center implantable cardioverter-defibrillator outcomes registry

Conditions: Arrhythmia

Summary: the primary objectives for the registry is to evaluate the overall incidence of serious complications or adverse events for primary implants and replacement devices, and assess the cost and time efficiency for both physicians and patients. the registry is a multi asc data collection registry. data collection will occur at the time of screening, implant, and 2 weeks after implant at the time of wound check.


Eligibility criteria:
inclusion criteria: * physician recommendation to receive the implant in an ambulatory surgical center (asc) exclusion criteria: * n/a
effect of cpap therapy on molecular breath patterns in patients with osa

Conditions: Obstructive Sleep Apnea

Summary: determination of changes in molecular breath patterns in osa patients, naïve for osa treatment before and after one month of cpap therapy by untargeted, secondary electrospray ionisation-high resolution mass spectrometry (sesi-hrms). furthermore, breath patterns will be assessed for correlation and association to clinical outcomes such as change in osa severity, sleepiness, and blood pressure.


Eligibility criteria:
inclusion criteria: * recently diagnosed osa (ahi ≥20/h) * patient is willing to start cpap therapy * ess \> 10 points * 18 years or above exclusion criteria: * moribund or severe disease prohibiting protocol adherence * use of oxygen therapy or home ventilation * physical or intellectual impairment precluding informed consent or protocol adherence * known malignancy, acute pulmonary disease, drug or alcohol abuse, known active inflammatory diseases (e.g. autoimmune disease), relevant congenital defects e.g. amino acid metabolism defect, relevant endocrinological disease, renal failure (gfr \< 15 ml/min) * pregnant patients

Keywords: exhaled breath analysis mass spectrometry
supply with micronutrients (purine and pyrimidine) in infants: a prospective and observational study

Conditions: Prematurity

Summary: concentrations of micronutrients (especially purine and pyrimidine) in cord blood, blood of mothers and infants and human milk is studied

collection of: 1. cord plasma in preterm and term infants. 2. remnants of clinically indicated blood samples of mothers 24 hours before or after birth. 3. remnants of clinically indicated blood samples of preterm and term infants during neonatal care. 4. breast milk once a weak during neonatal care of the infant. determination concentrations of micronutrients by mass spectrometry. aim is to compare cord plasma concentrations with postnatal plasma concentrations and to measure concentrations in breast milk to determine the actual supply. update september 2020: the results obtained according to the original protocol revealed a serious sample instability when using remnants of clinical blood samples. remnants can not be used and therefore the protocol had to be changed. a new approval of the ethics committee was obtained and is available to the study team. the following changes for sample collection were implemented: an additional blood sample (2.7ml edta blood) is taken from the mothers after approval.the blood samples of premature and newborns (max. 3x 0.2 ml) are obtained when a clinically indicated blood sample is taken. in both cases the serum is frozen immediately within one hour after collection. due to these changes, the expected end of the study is postponed to 2021.

Eligibility criteria:
inclusion criteria: * 23+0-42+6 ssw exclusion criteria: * congenital malformation, genetic disorders * metabolic disease of the infant * missing agreement

Keywords: infant cord micronutrients purine pyrimidine
four locator attachment mandibular overdentures

Conditions: Bone Resorption

Summary: . there is little information on the degree of crestal bone loss around 4 inter-foraminal implant-retained mandibular overdentures (ovds) and the amount of bone remodelling on the anterior maxilla and posterior mandibule on long-term function, particularly with different distributions.

numerous studies confirm the successful use of implants to retain prostheses in the edentulous atrophic mandible. it has been recommended by some authors that clinicians should use 3 or 4 implants in situations that require increased retention, such as high muscle attachment or prominent mylohyoid ridge. locator attachment as a retentive component has several advantages over other systems, such as: dual retention through both external and internal mating surfaces, a self-aligning feature which is helpful in guiding patients when placing their denture. there is little information on the degree of crestal bone loss around 4 inter-foraminal implant-retained mandibular overdentures (ovds) and the amount of bone remodelling on the anterior maxilla and posterior mandibule on long-term function, particularly with different distributions.

Eligibility criteria:
inclusion criteria: * patients with 4 implants in the inter-foraminal region. * patients treated by staff and students in the master's program in prosthodontics department according to the following criteria: * edentulous maxilla and mandible for at least 1 year. * problems with retention and stability of the mandibular denture. * mandibular bone height between 15 and 25 mm. exclusion criteria: * patients with relative contraindications, such as * a history of para functional habits. * smokers more than 10 cigarettes per day. * alcoholism. * patients with a history of radiation therapy in the head and neck region . • patients within intravenous administrated bisphosphonates., chemotherapy, and mental disorders that could jeopardies their co-operation.
avera cancer sequencing and analytics protocol (asap)

Conditions: Cancer; Cancer Diagnosis; Early Detection of Cancer; Breast Cancer; Lung Cancer; Colon Cancer; GI Cancer; Gynecologic Cancer; Ovarian Cancer; Endometrial Cancer; CNS Cancer; Hematologic Cancer

Summary: the purpose of this study is to understand the breadth of molecular characteristics present in participants cared for in a large integrated, community-based health care system. using comprehensive genomic profiling and proteomics, the investigators seek to identify the underlying genomic drivers of premalignant or malignant conditions in participants across different stages of disease development and cancer types. comprehensive molecular profiling will consist of somatic tumor testing (tissue and/or blood) using whole exome sequencing, whole transcriptome sequencing, proteomics, and selected instances of whole genome sequencing. in addition, the investigators seek to perform broad hereditary cancer testing in affected participant populations. hereditary testing has implications in screening, prognosis, and therapeutics for affected participants, as well as broad implications for genetic counseling and cascade testing. in order to maximize the value of genomic information, participants consented to this protocol will have their electronic health records (both retrospectively and prospectively) abstracted, curated, annotated and linked to genomic information obtained though the testing performed. given the long-term value of this data, participants will also be asked to voluntarily consent to have their samples stored in a biobank and have their de-identified information used for future research. information collected across this participant population will aid in advancing the investigators' knowledge of cancer biology, to discover and validate biomarkers associated with clinical outcomes, and shared in collaborative projects in order to promote the study of cancer.


Eligibility criteria:
inclusion criteria: * must be at least 18 years of age * must be undergoing a workup or being followed for a premalignant condition or have a diagnosis of cancer * must voluntarily sign and understand the most current irb-approved consent form prior to study participation exclusion criteria: * participants incapable of understanding the items listed in the consent form and process * participants with a history of or known psychiatric illness deemed unable to consent or adhere to study requirements

Keywords: cancer genomics genetics microbiome pharmacogenomics